ArticleThoracic cancer2026

PD-L1 Expression and Histopathological Features in EGFR-Mutated Non-Small Cell Lung Cancer: Implications for Immune Checkpoint Inhibitors After EGFR-Tyrosine Kinase Inhibitors Resistance.

Toshiyuki Sumi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.